Calidi Biotherapeutics Inc. Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, has shared a shareholder letter from CEO Eric Poma, PhD, detailing the company's progress and strategic direction for 2025. Under Poma's leadership since April 2025 and with Dr. Guy Travis Clifton joining as Chief Medical Officer, Calidi has made significant strides in advancing its RedTail platform. This innovative systemically delivered virotherapy targets metastatic cancers and delivers genetic payloads, with preclinical data presented at AACR and ASCO highlighting its tumor selectivity and immune modulation potential.

The company is actively engaging in partnership discussions and IND-enabling studies for its lead candidate, CLD-401, with an anticipated filing by the end of 2026. Additionally, Calidi has opened an IND for its intratumoral virotherapy, CLD-201, expecting Phase I trials to commence by year-end. Financially, Calidi reported a strong position with $10.6 million in cash at the end of Q1 and a significantly reduced burn rate, positioning the company to rapidly advance its pipeline while enhancing shareholder value.

Calidi Biotherapeutics' focus on developing systemic oncolytic targeted immunotherapies represents a promising avenue in the fight against cancer. The advancements in its RedTail platform and the progress towards clinical trials for CLD-401 and CLD-201 underscore the company's commitment to improving cancer treatment options. These developments not only highlight Calidi's innovative approach to oncology but also its potential to make a significant impact on patient care and the broader biotech industry.